A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab / interferon-α2a vs placebo / interferon-α2a as first-line therapy in metastatic renal cell carcinoma. - Escudier,B.; Koralwski,P.; Pluzanska,A. (J Clin Oncol, 2007)